ATL-001 is a cell therapy commercialized by Achilles Therapeutics, with a leading Phase II program in Metastatic Melanoma. According to Globaldata, it is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ATL-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ATL-001 is expected to reach an annual total of $44 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ATL-001 is under development for the treatment of advanced non-small cell lung cancer and metastatic or recurrent melanoma, head and neck squamous cell carcinoma. The therapeutic candidate comprises of clonal neoantigen T cells (cNeT) isolated from patients own tumor infiltrating lymphocytes (TILs). It is administered through intravenous route.
It was also under development for the treatment of renal cell carcinoma.
Achilles Therapeutics Overview
Achilles Therapeutics is a biopharmaceutical company focused on developing personalized T-cell therapies targeting neoantigens present on the surface of cancer cells. It’s lead indications for advanced non-small cell lung cancer and recurrent metastatic melanoma. Achilles uses its proprietary PELEUS bioinformatics platform to identify clonal neoantigens specific to that patient and enable the development of personalized cell therapies targeting cancer cells, without harming healthy tissues. It also operates in Stevenage, Hertfordshire, the UK. Achilles Therapeutics is headquartered in London, Greater London, UK.
The operating loss of the company was US$64.2 million in FY2021, compared to an operating loss of US$33.7 million in FY2020. The net loss of the company was US$61.1 million in FY2021, compared to a net loss of US$33.2 million in FY2020.
For a complete picture of ATL-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.